Clinical Trials Sponsored by Mabspace Biosciences (Suzhou) Co., Ltd.

Total 794 results

Suzhou Abogen Biosciences Co., Ltd.

Enrolling by invitation

A Study to Evaluate ABO2011 Monotherapy in Advanced Solid Tumors

Solid Tumor, Adult

China
Suzhou Junjing BioSciences Co., Ltd.

Terminated

A Study Explore WJ01075 Tablets in Patients With Advanced Solid Tumors

Advanced Solid Tumors

China
Suzhou Abogen Biosciences Co., Ltd.

Active, not recruiting

A Study to Evaluate Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Variant (COVID-19) mRNA Vaccines

COVID-19

Indonesia
Suzhou Junjing BioSciences Co., Ltd.

Recruiting

AP-L1898 Capsule in Patients With Non-small Cell Lung Cancer

Lung Cancer

China
Suzhou Abogen Biosciences Co., Ltd.

Active, not recruiting

A Study to Evaluate the Efficacy, Safety, and Immunogenicity of SARS-CoV-2 Variant (BA.4 /5) mRNA Vaccine

COVID-19

Philippines, Pakistan, United Arab Emirates, Indonesia
Suzhou Abogen Biosciences Co., Ltd.

Active, not recruiting

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Variant (COVID-19 Omicron) mRNA Vaccine (Phase 1)

COVID-19

United Arab Emirates
Suzhou Junjing BioSciences Co., Ltd.

Recruiting

The Safety and Efficacy of Multiple-dose of WJ01024 in Subject With Advanced Cancer

Advanced Solid Tumors | Advanced Hematologic Malignancies

China
Suzhou Neologics Bioscience Co., Ltd.

Not yet recruiting

A Dose Escalation and Expansion Study of NB002 in Participants With Advanced or Metastatic Solid Tumors

Advanced Solid Tumor
Suzhou Junjing BioSciences Co., Ltd.
Sponsor GmbH

Not yet recruiting

A Study of WJ05129 in Advanced Malignant Solid Tumors

Locally Advanced or Metastatic Malignant Solid Tumors

China
Suzhou Junjing BioSciences Co., Ltd.
Sponsor GmbH

Recruiting

A Phase I/II Study of WJ13404 Monotherapy in Patients With Advanced or Mentastatic Non-Small Cell Lung Cancer

Locally Advanced or Metastatic NSCLC

China
Anwita Biosciences
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

Phase 1 First-in-human Study of JS014

Lymphoma | Solid Tumor, Adult | Neoplasm Malignant | Neoplasm, Experimental

Taiwan
Suzhou Alphamab Co., Ltd.

Recruiting

Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B With Inhibitors

Hemophilia A With Inhibitor | Hemophilia B With Inhibitor

China
Suzhou Alphamab Co., Ltd.

Recruiting

Factor XI inhibiTion for the Prevention of Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty

Knee Arthroplasty, Total

China
Suzhou Alphamab Co., Ltd.

Recruiting

KN057 Multiple Dose Study in Moderately Severe to Severe Hemophilia

Hemophilia

China
Sciwind Biosciences APAC CO Pty. Ltd.
Hangzhou Sciwind Biosciences Co., Ltd.; Sciwind Biosciences USA Co., Ltd.

Withdrawn

Safety and Efficacy of Inhaled XW001 For Hospitalized COVID-19 Patients Requiring Oxygen Therapy

COVID-19 Acute Respiratory Distress Syndrome

Argentina, Peru
Shanghai Junshi Bioscience Co., Ltd.
Iqvia Pty Ltd; TopAlliance Biosciences, Inc.

Active, not recruiting

Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies

Advanced Malignancies

United States
3H (Suzhou) Pharmaceuticals Co., Ltd.

Not yet recruiting

A Study of 3HP-2827 in Treatment of Unresectable or Metastatic Solid Tumors With FGFR2 Alterations

Solid Tumors With FGFR2 Alterations, Adult

China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Recruiting

Early Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases

Systemic Lupus Erythematosus | Systemic Sclerosis | Idiopathic Inflammatory Myopathies | Primary Sjögren Syndrome | IgG4 Related Disease

China
Innovent Biologics (Suzhou) Co. Ltd.

Not yet recruiting

IBI3001 in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors

Locally Advanced Solid Tumor

Australia
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Recruiting

Study of SHR-8068 Combined With Adebrelimab and Platinum-containing Chemotherapy in the Treatment of Advanced Gastric and Esophageal Cancer

Advanced Gastric Adenocarcinoma and Esophageal Squamous Cell Carcinoma

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A First-in-human, Single-ascending-dose Study of IBI3002 in Healthy Participants and Mild to Moderate Asthmatics

Asthma | Healthy Participants

Australia
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Not yet recruiting

A Study of SHR-A1921 With or Without Carboplatin in Subjects With Ovarian Cancer

Ovarian Cancer
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Recruiting

A Study to Evaluate the Effect of Jaktinib on QT/QTc Interval in Healthy Participants

Healthy Participants

China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Recruiting

A Clinical Study to Compare the Safety and Pharmacokinetics of SHR-1314 Injection in Healthy Subjects at Different Specifications Devices

Moderate-to-Severe Plaque Psoriasis

China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Not yet recruiting

Phase I Study of SHR-2022 Injection in the Treatment of Patients With Advanced Malignant Tumors

Advanced Malignant Cancer
Suzhou Transcenta Therapeutics Co., Ltd.

Not yet recruiting

Combination of TST001, Nivolumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma

Gastric Cancer | Advanced Cancer | Gastroesophageal-junction Cancer
Suzhou BlueHorse Therapeutics Co., Ltd.

Not yet recruiting

A Clinical Study on TILs for the Treatment of Advanced Solid Tumors

Solid Tumor
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A Study of IBI112 in Chinese Patients With Psoriasis Who Were Previously Treated With Biologics

Psoriasis

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A Clinical Study of IBI130 for Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors

Solid Tumor

Australia
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Recruiting

Efficacy and Safety Study of Jaktinib in Subjects With Active Ankylosing Spondylitis(AS)

Ankylosing Spondylitis

China
Innovent Biologics (Suzhou) Co. Ltd.

Not yet recruiting

The Study of Tusamitamab Ravtansine (IBI126) Combined With Sintilimab and Tusamitamab Ravtansine (IBI126) Combined With Sintilimab Plus Platinum-based Chemotherapy and Pemetrexed in Subjects With CEACAM5 Positive Expression Advanced/Metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)

Non-squamous Non-small-cell Lung Cancer

China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Recruiting

A Study of SHR-A1811 Combined With Capecitabine in Treatment of Unresectable or Metastatic Breast Cancer With Low HER2 Expression.

Breast Cancer

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Not yet recruiting

Efficacy and Safety of Jaktinib in Participants With Severe Novel Coronavirus Pneumonia(COVID-19) (COVID-19)

COVID-19 | Pneumonia

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Recruiting

A Phase III Extended Clinical Trial of Jaktinib Hydrochloride Tablets in the Treatment of Moderate and Severe Atopic Dermatitis

Atopic Dermatitis

China
MediLink Therapeutics (Suzhou) Co., Ltd.

Recruiting

A Study of YL202 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer and Breast Cancer

Breast Cancer | Non Small Cell Lung Cancer

United States, China
Innovent Biologics (Suzhou) Co. Ltd.

Not yet recruiting

A First-in-human Study of IBI354 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors

Locally Advanced Unresectable or Metastatic Solid Tumors

Australia
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

Efficacy and Safety of IBI351 in Combination With Sintilimab ± Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C Mutation

Advanced Non-Small Cell Lung Cancer

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A Study of IBI351 in Combination With Cetuximab in Subjects With KRAS G12C Mutated Metastatic Colorectal Cancer

Colorectal Cancer

China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Recruiting

TAA05 Injection in the Treatment of Adult Patients With FLT3-positive Relapsed/Refractory Acute Myeloid Leukemia

FLT3-positive Relapsed/Refractory Acute Myeloid Leukemia

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A Phase 1, Open-label, Multicenter, Dose Escalation Study of IBI363 (PD1-IL2m) in Subjects With Advanced Solid Malignancies or Lymphomas

Solid Malignancies or Lymphomas

Australia
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Recruiting

A Safety and Tolerability Study of Jaktinib

Myelofibrosis

United States
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Recruiting

Extension Study to Evaluate Safety and Efficacy of Jaktinib in Adults With Alopecia Areata (AA)

Alopecia Areata

China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Recruiting

A Study of SHR-1701 Plus Platinum-containing Chemotherapy With or Without BP102 (Bevacizumab) as First-line Treatment in Cervical Cancer

Cervical Cancer

China
Innovent Biologics (Suzhou) Co. Ltd.

Not yet recruiting

A Phase Ib Study of Primary Efficacy and Safety of IBI321 Monotherapy or Combination Therapy in Patients With Advanced Solid Tumors

Advanced Solid Tumors

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

Safety and Efficacy of IBI389 Single Agent, and in Combination With Sintilimab, in Patients With Advanced Malignancies

Advanced Solid Tumors

China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Not yet recruiting

A Study of SHR-1701 Plus Bevacizumab and Chemotherapy in Non-Small-Cell-Lung-Cancer

Advanced or Metastatic Non-squamous Non-small-cell Lung Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Not yet recruiting

Study of SHR-1701 Plus BP102 in Subjects With Selected Solid Tumors

Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Not yet recruiting

A Phase II Study to Evaluate the Efficacy and Safety of SHR-1314 in Lupus Nephritis

Lupus Nephritis
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Recruiting

Trial of SHR-1701 Plus BP102 in Subjects With Selected Solid Tumors

Advanced Solid Tumors

China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Recruiting

A Clinical Studyf of SHR-1701 or Placebo in Combination With BP102 and XELOX in the First-line Treatment of mCRC

Metastatic Colorectal Cancer (mCRC)

China

Clinical Trials Sponsored by Mabspace Biosciences (Suzhou) Co., Ltd.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Vietnam

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations